Liver disease Archives

More News! 4 Nov 2022

Alimentiv and Summit collaborate to tackle liver disease NASH

Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit Clinical Research, in a bid to tackle non-alcoholic steatohepatitis (NASH). They announced a strategic alliance to tackle the now growing global epidemic with no approved treatments. It says that current challenges include optimizing and end-point assessment, minimizing screen failures and […]

November 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 10 Oct 2022

Biocartis starts European commercialization of liver cancer test

Biocartis Group NV has started the commercialization in Europe of the HepatoPredict test as a CE-IVD marked manual kit. The test, developed by Portuguese biotech company Ophiomics, is a prognostic diagnostic test that supports the decision of liver transplantation in patients with hepatocellular carcinoma (HCC). Herman Verrelst, chief executive officer of Biocartis, said: “We are […]

October 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Sep 2022

GENFIT to acquire Versantis to expand liver disease portfolio

GENFIT has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. GENFIT said the acquisition fits its strategic vision of becoming a global leader in ACLF (acute-on-chronic […]

September 19, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 28 Jun 2022

Companies unite to bolster diagnostics for cancer and liver disease

Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease and breast cancer have partnered in a bid to bolster noninvasive diagnostics for the conditions. IV Bio-holdings (IVBH), a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improves the detection, diagnosis and treatment of disease […]

June 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Jun 2022

Eiger BioPharmaceuticals presents liver study data

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharma company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, has announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 that took place June 22-26 in London, U.K. David Cory, […]

June 28, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 19 Jan 2022

Engitix Builds Liver Disease Pipeline with Series A and Drug Collaboration

With the close of its Series A round at €48M ($54M), the tissue models company Engitix has shifted its business from providing drug discovery services to developing its own treatment pipeline for liver diseases. When Engitix was spun out of University College London in 2016, the startup primarily aimed to provide tissue models to pharmaceutical […]

January 19, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 21 Jan 2020

German Biotech Raises €11M to Regenerate Liver Damage

Biotech company HepaRegeniX has raised a Series B round that will allow its first candidate drug for liver disease to enter clinical trials later this year. Based in Tübingen, Germany, HepaRegenix was founded in 2017 with a €9M Series A round. The same investors are now taking part in a Series B round […]

January 21, 2020 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Dec 2019

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M with the addition of new investors, including Innovation Growth Ventures and Pegasus Tech Ventures among others. The round will fund two ongoing clinical trials and the start of at least two new trials outside Europe. Published on 07/05/2019 The Belgian […]

December 17, 2019 - 2 minutesmins - By Jonathan Smith

More News! 18 Sep 2019

€15M to Take Swiss Biotech’s Liver Cirrhosis Treatment to Phase II

Versantis has raised a Series B of €14.6M (CHF 16M) to advance its treatment for late-stage liver cirrhosis to a phase IIa trial. The money will finance the completion of an ongoing phase I trial of Versantis’ lead candidate for the condition decompensated liver cirrhosis. Following this, the company will use the funds to launch […]

September 18, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 2 May 2019

Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Treat Patients

Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary cholangitis failed to reduce a key disease biomarker in a phase II trial, but showed potential for reducing liver scarring. Primary biliary cholangitis is an autoimmune disease that damages the liver and can lead to liver scarring (fibrosis) or the […]

May 2, 2019 - 2 minutesmins - By Jonathan Smith

liver fibrosis alentis switzerland cirrhosis cancer

News and Trends 30 Apr 2019

Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis

Founded in March this year, Alentis Therapeutics has bagged a Series A round of €11.1M (CHF 12.5M) to develop antibody drugs treating liver fibrosis, which currently has no approved treatments. Liver fibrosis is the scarring of liver tissue, which can happen as a consequence of aging, chronic hepatitis or conditions such as non-alcoholic steatohepatitis (NASH). […]

April 30, 2019 - 2 minutesmins - By Jonathan Smith

promethera liver failure stem cell therapy

News and Trends 15 Apr 2019

First Stem Cell Therapy for Liver Failure Shows Promise in First Human Trials

A stem cell therapy developed by the Belgian company Promethera has improved symptoms, such as jaundice, in patients with acute liver failure, a condition with no effective treatments. A phase I/IIa trial of the therapy recruited 19 patients with chronic liver disease. Of these,12 patients had developed acute-on-chronic liver failure, a life-threatening syndrome where the […]

April 15, 2019 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us